Education
About Us
Working with TipRanks
Follow Us
Bioxcel Therapeutics Inc (BTAI)
NASDAQ:BTAI
BTAI Stock Chart & Stats
$1.73
-$0.09(-19.80%)
At close: 4:00 PM EST
$1.73
-$0.09(-19.80%)
Day’s Range― - ―
52-Week Range$1.17 - $9.25
Previous CloseN/A
Volume1.10M
Average Volume (3M)1.58M
Market Cap
$37.83M
Enterprise Value$104.56M
Total Cash (Recent Filing)$37.32M
Total Debt (Recent Filing)$109.29M
Price to Earnings (P/E)―
Beta2.06
Next Earnings
Mar 05, 2026EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.18
Shares Outstanding21,869,492
10 Day Avg. Volume1,230,633
30 Day Avg. Volume1,584,008
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.16
Price to Sales (P/S)6.69
P/FCF Ratio-0.21
Enterprise Value/Market Cap2.76
Enterprise Value/Revenue139.04
Enterprise Value/Gross Profit-364.33
Enterprise Value/Ebitda-2.04
Forecast
1Y Price Target
$10.00Price Target Upside478.03% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyBXCL501 demonstrated a significant mean reduction in the modified Clinical Global Impression–Severity score from baseline compared to placebo, indicating robust and sustainable clinical impact.
Market ComplianceNASDAQ listing compliance reclaimed based on recovery in market value of listed securities.
Regulatory ApprovalThe favorable data from the SERENITY At-Home trial should be sufficient to warrant label extension.
Bears Say
Trial DelaysRisks include, but are not limited to: delays in completing trials with BXCL501 and BXCL701.
Bioxcel Therapeutics News
BTAI FAQ
What was Bioxcel Therapeutics Inc’s price range in the past 12 months?
Bioxcel Therapeutics Inc lowest stock price was $1.17 and its highest was $9.25 in the past 12 months.
What is Bioxcel Therapeutics Inc’s market cap?
Bioxcel Therapeutics Inc’s market cap is $37.83M.
When is Bioxcel Therapeutics Inc’s upcoming earnings report date?
Bioxcel Therapeutics Inc’s upcoming earnings report date is Mar 05, 2026 which is in 73 days.
How were Bioxcel Therapeutics Inc’s earnings last quarter?
Bioxcel Therapeutics Inc released its earnings results on Nov 12, 2025. The company reported -$2.18 earnings per share for the quarter, missing the consensus estimate of -$1.34 by -$0.84.
Is Bioxcel Therapeutics Inc overvalued?
According to Wall Street analysts Bioxcel Therapeutics Inc’s price is currently Undervalued.
Does Bioxcel Therapeutics Inc pay dividends?
Bioxcel Therapeutics Inc does not currently pay dividends.
What is Bioxcel Therapeutics Inc’s EPS estimate?
Bioxcel Therapeutics Inc’s EPS estimate is -0.84.
How many shares outstanding does Bioxcel Therapeutics Inc have?
Bioxcel Therapeutics Inc has 21,869,492 shares outstanding.
What happened to Bioxcel Therapeutics Inc’s price movement after its last earnings report?
Bioxcel Therapeutics Inc reported an EPS of -$2.18 in its last earnings report, missing expectations of -$1.34. Following the earnings report the stock price went down -15.347%.
Which hedge fund is a major shareholder of Bioxcel Therapeutics Inc?
Currently, no hedge funds are holding shares in BTAI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bioxcel Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$10.00 (478.03% Upside)
$10.00 (478.03% Upside)
Hedge Fund Trend
Decreased
By 1.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.70%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-60.59%
Trailing 12-Months
Company Description
Bioxcel Therapeutics Inc
Bioxcel Therapeutics, Inc. (BTAI) is a biopharmaceutical company that leverages artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology. The company is focused on discovering, developing, and commercializing innovative therapies through its proprietary AI platform designed to identify new therapeutic opportunities. Their core areas include treatments for acute agitation in patients with neuropsychiatric disorders and therapies targeting rare forms of cancer.
BTAI Stock 12 Month Forecast
Average Price Target
$10.00
▲(478.03% Upside)
Technical Analysis
Actinium Pharmaceuticals
―
Kezar Life Sciences
―
Annovis Bio
―
BioAtla
―
Century Therapeutics
―
Ownership Overview
2.65% Insiders
1.86% Mutual Funds
1.64% Other Institutional Investors
93.28% Public Companies and Individual Investors